LONGEVITY9 min read·June 18, 2026

GLP-1s and Biological Aging: What the Epigenetic Data Shows

A small RCT signal suggests semaglutide may slow the pace of biological aging on an epigenetic clock. Here is the evidence, the caveats, and what to track.

GLP-1s and Biological Aging: What the Epigenetic Clocks Actually Show **Does semaglutide or a GLP-1 slow biological aging? The most direct evidence to date is a single, small randomized placebo-controlled study from UC San Diego (presented around CROI 2025 and widely discussed into 2026) that reported semaglutide slowed the *pace* of biological aging by roughly 9% on the DunedinPACE epigenetic clock over about 32 weeks. Read that finding with the caveats attached: this was a small trial (about 32 participants), it measured a surrogate epigenetic marker rather than any health or longevity outcome, and a result this size needs replication before anyone should treat it as settled. It is a genuinely interesting early signal, not proof that a GLP-1 slows, stops, or reverses aging.** This post walks through what that study found, how it fits with a much larger observational analysis on mortality, what the proposed mechanisms are, and most importantly, how you can track the biomarkers behind "biological age" over time instead of relying on a single number. This is education, not medical advice. Decisions about [semaglutide](/peptides/semaglutide), [tirzepatide](/peptides/tirzepatide), or any prescription belong with your own clinician.

What Is "Biological Age," and Why Epigenetic Clocks?

Chronological age counts birthdays. Biological age is an attempt to estimate how old your body seems at the molecular and physiological level, which can run ahead of or behind the calendar depending on genetics, metabolic health, inflammation, and lifestyle.

The current generation of biological-age estimates leans heavily on epigenetic clocks. These read DNA methylation, a chemical tagging pattern on your DNA that shifts in predictable ways as you age. Two ideas matter here:

•**First-generation clocks** (like Horvath and Hannum) estimate an age in years from methylation patterns.

•**DunedinPACE** is different and is the clock used in the GLP-1 study. Instead of estimating how old you are, it estimates *how fast you are currently aging*, expressed as a rate. A DunedinPACE of 1.0 means roughly one biological year per chronological year; below 1.0 suggests a slower pace, above 1.0 a faster one.

The appeal of a "pace" measure is that it can move on a timescale of months, which is why a 32-week drug study could even detect a change. The limitation is that it is still a surrogate. A slower methylation pace is a hypothesis-generating signal, not a demonstrated reduction in disease or death. Interpreting any single clock reading clinically is not the point here. Tracking the trend in your own markers over time is.

The UC San Diego Study: The First RCT-Level Signal

Here is the finding that drove the headlines, stated carefully.

Researchers at UC San Diego ran a randomized, placebo-controlled study and reported the first RCT-level signal that semaglutide slowed the pace of biological aging by approximately 9% on the DunedinPACE epigenetic clock over roughly 32 weeks compared with placebo.

Now the caveats, which matter as much as the result:

•**Small sample.** The study included only about **32 participants**. Effects measured in groups this small can shrink, vanish, or reverse when tested in larger populations. This is the single most important thing to remember about the finding.

•**Surrogate endpoint.** It measured an **epigenetic marker**, not a clinical outcome. No one in this trial was shown to live longer, avoid disease, or stay healthier as a result. The clock moved; that is the entire claim.

•**Not a longevity trial.** Demonstrating that a drug extends human lifespan or healthspan requires very large, very long studies. This was neither.

So the honest summary is: a small, well-designed trial found that semaglutide may be associated with a slower epigenetic pace of aging over eight months. That is a reason for more research, not a reason to claim a GLP-1 is an anti-aging therapy.

The Larger Mortality Signal (Observational, Not Causal)

Separately, a 2025 analysis published in JAMA Network Open looked at more than 60,000 adults and found that semaglutide or tirzepatide use was associated with lower all-cause mortality, and with lower risk of stroke and dementia, versus comparator treatments.

This is a much larger dataset, which is encouraging, but the design carries its own limit that cuts the opposite way from the RCT:

•It is **observational**. It shows an **association**, not proven causation. People prescribed and able to stay on these medications may differ in important ways from those who are not (access, adherence, baseline health, healthcare engagement). Those differences can create or inflate an apparent benefit.

Put the two studies together and you get a coherent but unproven story: a small randomized trial nudges a surrogate aging marker in the expected direction, and a large observational dataset associates the same drug class with better hard outcomes. Neither one closes the loop on causation for aging. Both point at the same place, which is why the topic is worth tracking rather than dismissing.

### Evidence at a glance

The Proposed Mechanisms (Frame These as Hypotheses)

If a GLP-1 really does influence aging biomarkers, *why* might that happen? The leading explanations are well-established physiological pathways, but their link to *aging* specifically is still a hypothesis, not an established mechanism. Three candidates:

•**Weight loss.** Substantial fat loss, particularly visceral fat, changes metabolic and inflammatory signaling throughout the body. Excess adiposity is associated with accelerated aging markers, so reducing it is a plausible route by which the pace could slow.

•**Reduced inflammation.** GLP-1 receptor agonists are associated with lower systemic inflammation. A common readout is [hs-CRP](/biomarkers/hs-crp) (high-sensitivity C-reactive protein). Chronic low-grade inflammation, sometimes called "inflammaging," is one of the more consistent correlates of biological aging, so a drop here is a mechanistically sensible pathway.

•**Improved insulin sensitivity.** Better glucose handling, often visible as a falling [HbA1c](/biomarkers/hba1c), reduces the metabolic stress that contributes to cellular aging.

None of these is a proven anti-aging mechanism. They are reasonable bridges between "this drug improves metabolic health" and "aging biomarkers shifted." The value for you is that each of these pathways is trackable with a standard blood draw, which brings us to the practical part.

What to Track: Biological Age and the Markers Behind It

You do not need a research lab to follow your own trend. There are two tiers, and the cheaper tier is where most people should start.

Tier 1: The direct epigenetic clocks. Consumer DunedinPACE and methylation-clock tests exist. They are the closest thing to what the study measured, but they cost more, are sensitive to collection conditions, and a single reading carries real noise. They are most useful as an occasional anchor, tracked over a long horizon rather than month to month.

Tier 2: The biomarker proxies (start here). The widely studied PhenoAge approach estimates biological age from a panel of inexpensive, standard blood markers rather than methylation. Its inputs are the kind of labs many people already get, including:

•**[hs-CRP](/biomarkers/hs-crp)** for inflammation

•**[HbA1c](/biomarkers/hba1c)** and fasting glucose for glucose control

•**Albumin** and **creatinine** for organ and metabolic status

•Plus markers like white blood cell count, alkaline phosphatase, and others

These move on the same metabolic pathways the GLP-1 mechanisms run through, they are cheap to repeat, and they are far less noisy as a *trend* than a one-off clock reading. It is also worth following [ApoB](/biomarkers/apob) alongside them, since cardiometabolic risk is part of the larger aging picture even though it is not a PhenoAge input.

The point of tracking is not to diagnose yourself or to interpret a single value. It is to watch direction over time. If you are working with a clinician on any metabolic protocol, a clean before-and-after of your own inflammation and glucose markers is far more informative than a headline about someone else's study.

[Track your biological-age markers over time with MyProtocolStack.](/auth/login?mode=signup)

For deeper background, see our guides on [biological age markers](/blog/biological-age-markers) and how to build a [longevity blood panel](/blog/longevity-blood-panel), or browse the full [biomarker library](/biomarkers).

How to Read News Like This Without Getting Burned

The GLP-1-and-aging story is a useful case study in evidence literacy. A few habits travel well beyond this one topic:

•**Check the sample size first.** A 9% effect in 32 people and a 9% effect in 30,000 people are not the same claim. Small studies are where exciting signals are born and also where many of them die.

•**Separate surrogate from outcome.** "An epigenetic clock moved" is a different statement from "people lived longer or got sick less often." Both matter, but only the second one is what most people actually care about, and the first does not guarantee the second.

•**Separate association from causation.** Large observational datasets are valuable for generating hypotheses and spotting safety signals, but a correlation between a prescription and an outcome can be driven by who gets prescribed it.

•**Track your own data.** The most actionable thing in this entire field is not any single study. It is your own trend line on cheap, repeatable markers like hs-CRP and HbA1c, measured consistently over months.

Frequently Asked Questions

Does semaglutide slow biological aging?

A small randomized, placebo-controlled UC San Diego study (presented around CROI 2025) reported that semaglutide slowed the pace of biological aging by about 9% on the DunedinPACE epigenetic clock over roughly 32 weeks. It is an early signal worth noting, but the study was small (about 32 participants) and measured a surrogate marker, not a health or longevity outcome. It does not establish that semaglutide slows or reverses aging.

What is the DunedinPACE epigenetic clock?

DunedinPACE is a DNA-methylation-based measure that estimates the *rate* at which someone is currently aging rather than their total biological age. A value near 1.0 reflects roughly one biological year per chronological year; lower suggests a slower pace. It was the clock used in the semaglutide study, and because it can shift over months, it is the kind of marker a relatively short trial could detect.

Do GLP-1 drugs reduce the risk of death or dementia?

A 2025 JAMA Network Open analysis of more than 60,000 adults associated semaglutide or tirzepatide use with lower all-cause mortality and lower risk of stroke and dementia versus comparators. This is observational, so it shows an association rather than proven causation, and people who take these drugs may differ from those who do not in ways that affect the result.

How can I track my own biological age?

The most accessible approach is to track the inexpensive blood markers behind biological-age estimates like PhenoAge, including hs-CRP, HbA1c, fasting glucose, albumin, and creatinine. Direct epigenetic clock tests (such as consumer DunedinPACE panels) exist but cost more and are noisier as one-off readings. The goal is to follow your trend over time, not to interpret any single number as a diagnosis. You can log and chart these markers with MyProtocolStack.

Is it proven that GLP-1s extend lifespan?

No. No study has shown that a GLP-1 extends human lifespan. The current evidence is a small randomized trial moving a surrogate epigenetic marker and a large observational dataset associating the drug class with better outcomes. Both are reasons for further research, not evidence that these medications are anti-aging or life-extending therapies.

Sources

1. UC San Diego Today, "Study: Popular GLP-1 Drug May Slow Down Biological Aging." https://today.ucsd.edu/story/study-popular-glp-1-drug-may-slow-down-biological-aging

2. University of California, "New study shows popular GLP-1 weight-loss drug may slow biological aging." https://www.universityofcalifornia.edu/news/new-study-shows-popular-glp-1-weight-loss-drug-may-slow-biological-aging

3. Medical News Today, "GLP-1 drugs (Ozempic, Wegovy) may slow biological aging." https://www.medicalnewstoday.com/articles/glp-1-drugs-ozempic-wegovy-may-slow-biological-aging

*This article is for educational purposes only and is not medical advice, diagnosis, or treatment guidance. The research described is early and, in the case of the epigenetic study, based on a very small sample measuring a surrogate marker rather than a health outcome. Nothing here should be used to start, stop, or change any medication. Talk to a qualified healthcare professional about your own situation. MyProtocolStack is a tracking and education tool, not a provider of medical care.*

MENTIONED IN THIS POST

PEPSemaglutide PEPTirzepatide BIOAlbumin BIOApoB BIOCreatinine BIOFasting Glucose BIOHbA1c BIOhs-CRP BIOWBC

Track Your Labs. Build Your Protocol.

Enter your blood work in MyProtocolStack, run StackAI analysis, and get personalized insights based on your actual numbers — not generic charts.

Start Free →

Not medical advice. Always consult a qualified healthcare provider before starting any peptide protocol. Read full disclaimer →

Free: Peptide Blood Work Checklist

The complete biomarker tracking checklist for peptide protocols - baseline panels, on-protocol monitoring by peptide type, and testing timelines. Download instantly.

No spam. Unsubscribe anytime.